Pharmaceutical composition containing neuregulin isoforms

Abstract

A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications.

1 . A pharmaceutical composition comprising a polypeptide which is a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β and a pharmaceutically acceptable excipient, wherein said recombinant soluble Type I Neuregulin-1 β isoform is characterized in that it is capable of crossing the blood-brain barrier and is non-mutagenic in a mouse lymphoma thymidine kinase locus assay. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform comprises the extracellular domain of Type I Neuregulin-1 β and has a molecular mass of between 25 and 32 kD. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform comprises the extracellular domain of Type I Neuregulin-1 β and has a molecular mass of about 26 kD. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform has an isoelectric point (pl) of about 4 to about 10. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said composition is formulated to be injectable. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein said composition is formulated to be injectable by intravenous (i.v.) injection. 
     
     
         9 . The pharmaceutical composition of  claim 7 , wherein said composition is formulated to be injectable by subcutaneous (s.c.) injection. 
     
     
         10 . The pharmaceutical composition of  claim 7 , wherein said composition is formulated to be injectable by intraperitoneal (i.p.) injection. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein said composition is formulated to be an inhalation product. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein said composition is formulated to be administered systemically. 
     
     
         13 . The pharmaceutical composition of  claim 1 , further comprising a medicament for the treatment of neurological conditions. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the further medicament is selected from the group consisting of acetylcholine esterase inhibitors, MAO-B-inhibitors, COMT-inhibitors, Memantine-type channel blockers, dopamine receptor agonists, serotonine receptor agonists or antogonists, catecholamine reuptake inhibitors, serotonine reuptake inhibitors. 
     
     
         15 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of psychotic disorders. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of Parkinson's disease. 
     
     
         17 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of Alzheimer's disease. 
     
     
         18 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of Multiple Sclerosis (MS). 
     
     
         19 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of Amyotrophic Lateral Sclerosis (ALS). 
     
     
         20 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of epilepsy. 
     
     
         21 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of stroke. 
     
     
         22 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of traumatic brain injury. 
     
     
         23 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of spinal cord injury. 
     
     
         24 . The pharmaceutical composition of  claim 13 , wherein the further medicament is selected from clozapine, olanzapine, or gabapentin. 
     
     
         25 . The pharmaceutical composition of  claim 13 , wherein the further medicament is a medicament for the treatment of schizophrenia, bipolar disorders or depression.